Premium
Indirect comparison of anti‐interleukin 17 targeted biological treatments for moderate‐to‐severe psoriasis
Author(s) -
Díaz Acedo Rocío,
Galvan Banqueri Mercedes,
Márquez Saavedra Esther
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13153
Subject(s) - secukinumab , ixekizumab , medicine , psoriasis area and severity index , ustekinumab , psoriasis , interleukin 17 , randomized controlled trial , dermatology , cochrane library , confidence interval , adalimumab , disease , cytokine , psoriatic arthritis
What is known and objective Psoriasis is an inflammatory skin disease with an important disease burden worldwide and its treatment includes systemic therapies which have advanced over time to target specific immune cytokines such as interleukin‐17. The main objective of this study was to compare the relative efficacy of brodalumab, ixekizumab and secukinumab (three anti‐interleukin‐17 drugs) through adjusted indirect treatment comparisons (ITCs). Methods A search was carried out in June 2019, consulting these databases: MEDLINE, EMBASE, Web of Science and the Cochrane Library. Studies including patients with moderate to severe psoriasis randomized to receive treatment with anti‐interleukin‐17 drugs or ustekinumab and with outcomes such as Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 scores or static Physician's Global Assessment (sPGA), were included. ITCs were carried out using the method proposed by Bucher et al Results and discussion Five randomized clinical trials were included. Analysing short‐term data, there were no statistically significant differences between any pair of drugs in terms of PASI 75, PASI 100 or sPGA/sIGA 0/1. Analysing long‐term data, statistically significant differences were only observed for secukinumab versus brodalumab in terms of PASI 100 (Absolute risk reduction −12.9%; 95% confidence interval −22.7% to −3.1%). What is new and conclusion The ITCs indicated no efficacy differences between anti‐interleukin‐17 drugs, except for secukinumab versus brodalumab 52‐week analysis in terms of achieving PASI 100. All three drugs appear to act as equivalent clinical treatments for psoriasis. However, independent head‐to‐head trials should be carried out.